Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

To further investigate potential mechanisms of resistance to FLT3 inhibitors, we developed a resistant cell line by long-term culture of MV4-11 cells with ABT-869, designated as MV4-11-R. Gene profiling reveals up-regulation of FLT3LG (FLT3 ligand) and BIRC5 (survivin), but down-regulation of SOCS1, SOCS2, and SOCS3 in MV4-11-R cells. Hypermethylation of these SOCS genes leads to their transcriptional silencing. Survivin is directly regulated by STAT3. Stimulation of the parental MV4-11 cells with FLT3 ligand increases the expression of survivin and phosphorylated protein STAT1, STAT3, STAT5. Targeting survivin by short-hairpin RNA (shRNA) in MV4-11-R cells induces apoptosis and augments ABT-869-mediated cytotoxicity. Overexpression of survivin protects MV4-11 from apoptosis. Subtoxic dose of indirubin derivative (IDR) E804 resensitizes MV4-11-R to ABT-869 treatment by inhibiting STAT signaling activity and abolishing survivin expression. Combining IDR E804 with ABT-869 shows potent in vivo efficacy in the MV4-11-R xenograft model. Taken together, these results demonstrate that enhanced activation of STAT pathways and overexpression of survivin are important mechanisms of resistance to ABT-869, suggesting that the STAT pathways and survivin could be potential targets for reducing resistance developed in patients receiving FLT3 inhibitors.

[1]  Hanry Yu,et al.  In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. , 2008, Leukemia research.

[2]  T. Golub,et al.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.

[3]  J. Sampath,et al.  Alternative splice variants of survivin as potential targets in cancer. , 2007, Current drug discovery technologies.

[4]  D. Hilton,et al.  The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways , 2007, Current opinion in hematology.

[5]  Kyu-Tae Kim,et al.  Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. , 2006, Blood.

[6]  S. Fukuda,et al.  Survivin, a cancer target with an emerging role in normal adult tissues , 2006, Molecular Cancer Therapeutics.

[7]  G. Stassi,et al.  Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. , 2006, Cancer research.

[8]  M. Andreeff,et al.  Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. , 2006, Blood.

[9]  S. Eschrich,et al.  Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[10]  J. Sampath,et al.  Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. , 2005, Cancer research.

[11]  J. Darnell,et al.  Validating Stat3 in cancer therapy , 2005, Nature Medicine.

[12]  K. Glaser,et al.  Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor , 2005, Molecular Cancer Therapeutics.

[13]  Wolfgang Hiddemann,et al.  FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). , 2005, Blood.

[14]  J. Turkson,et al.  Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Chakravarti,et al.  Survivin mediates resistance to antiandrogen therapy in prostate cancer , 2005, Oncogene.

[16]  J. Licht,et al.  Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges , 2005, Current opinion in hematology.

[17]  Y. Shukla,et al.  Ultraviolet-B Radiation Causes an Upregulation of Survivin in Human Keratinocytes and Mouse Skin¶ , 2004, Photochemistry and photobiology.

[18]  Sergio Wittlin,et al.  Differential hypermethylation of SOCS genes in ovarian and breast carcinomas , 2004, Oncogene.

[19]  Doriano Fabbro,et al.  Prediction of Resistance to Small Molecule FLT3 Inhibitors , 2004, Cancer Research.

[20]  M. Emi,et al.  Suppressor of cytokine signalling‐1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines , 2004, British journal of haematology.

[21]  W. Hiddemann,et al.  Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. , 2004, Blood.

[22]  M. Cazzola,et al.  Survivin Expression in Acute Leukemias and Myelodysplastic Syndromes , 2004, Leukemia & lymphoma.

[23]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[24]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[25]  D. Collen,et al.  Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. , 2003, The American journal of pathology.

[26]  S. Chiou,et al.  Survivin expression in the stomach: implications for mucosal integrity and protection. , 2003, Biochemical and biophysical research communications.

[27]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[28]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[29]  M. Daidone,et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer , 2002, Cellular and Molecular Life Sciences CMLS.

[30]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[31]  D. Altieri,et al.  The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.

[32]  S. Fukuda,et al.  Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. , 2001, Blood.

[33]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[34]  J. Pober,et al.  Interleukin-11 Up-Regulates Survivin Expression in Endothelial Cells through a Signal Transducer and Activator of Transcription-3 Pathway , 2001, Laboratory Investigation.

[35]  F. Sigaux,et al.  Expression and prognostic significance of survivin in de novo acute myeloid leukaemia , 2000, British journal of haematology.

[36]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[37]  E Springer,et al.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. , 1999, Cancer research.

[38]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[39]  Z. Xia,et al.  Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. , 1998, Cancer research.

[40]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[41]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[42]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[43]  D. Birnbaum,et al.  Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. , 1996, Leukemia.

[44]  H. Broxmeyer,et al.  Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. , 1995, Experimental hematology.

[45]  D. Birnbaum,et al.  Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. , 1995, Leukemia.

[46]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Glaser,et al.  Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway , 2008, Leukemia.

[48]  D. Altieri.  Survivin, cancer networks and pathway-directed drug discovery , 2008, Nature Reviews Cancer.

[49]  Jin-Hua Han,et al.  Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. , 2007, Experimental hematology.

[50]  D. Small,et al.  FLT3 mutations: biology and treatment. , 2006, Hematology. American Society of Hematology. Education Program.

[51]  R. Stone,et al.  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. , 2006, Blood.

[52]  D. Hicklin,et al.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. , 2004, Blood.

[53]  D. Fabbro,et al.  Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412 , 2002 .

[54]  B. Groner,et al.  STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. , 1996, Blood.